• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    [email protected]



    Media Relations for REPAY:

    Kristen Hoyman

    [email protected]

    Get the next $CNDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    11/13/2025$105.00Sector Outperform
    Scotiabank
    Fiserv Inc.
    $FI
    11/5/2025$62.00Outperform → Neutral
    BNP Paribas Exane
    Fiserv Inc.
    $FI
    10/30/2025Buy → Hold
    Argus
    Fiserv Inc.
    $FI
    10/30/2025Buy → Neutral
    B. Riley Securities
    Fiserv Inc.
    $FI
    10/30/2025$79.00Buy → Neutral
    Goldman
    Fiserv Inc.
    $FI
    10/30/2025Buy → Neutral
    Seaport Research Partners
    Fiserv Inc.
    $FI
    10/30/2025$80.00Buy → Hold
    TD Cowen
    Fiserv Inc.
    $FI
    10/30/2025$81.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Solutions by Text and Conduent Partner to Modernize Loan Servicing with Integrated, Compliant Text Messaging

    SBT's mobile engagement messaging platform integrates into Conduent's Loan Manager platform to boost on-time payments and borrower engagement DALLAS, Nov. 13, 2025 /PRNewswire/ -- Solutions by Text (SBT), a leader in compliance-first conversational commerce solutions today announced a collaboration with Conduent (NASDAQ:CNDT), a global technology-driven business solutions and services provider, to integrate SBT's consumer-centric mobile messaging platform directly into Conduent's Loan Manager, a digital cloud-based solution for loan and lease servicing platform, to improve operational performance and boost customer satisfaction.

    11/13/25 9:10:00 AM ET
    $CNDT
    Real Estate

    Merck to Participate in the Jefferies Global Healthcare Conference in London

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 20, 2025, at 9:30 a.m. ET / 2:30 p.m. GMT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: W

    11/13/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fiserv Inc.

    SCHEDULE 13G/A - FISERV INC (0000798354) (Subject)

    11/13/25 4:43:12 PM ET
    $FI
    Real Estate

    SEC Form SCHEDULE 13G filed by Repay Holdings Corporation

    SCHEDULE 13G - Repay Holdings Corp (0001720592) (Subject)

    11/13/25 12:05:33 PM ET
    $RPAY
    Real Estate

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    11/12/25 4:11:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Comm. & Public Afrs Ofcr Downing Cristal N sold $616,395 worth of shares (7,085 units at $87.00), closing all direct ownership in the company (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    11/12/25 4:01:31 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    New insider Todd Paul M claimed ownership of 7,453 shares (SEC Form 3)

    3 - FISERV INC (0000798354) (Issuer)

    11/4/25 4:13:17 PM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Director Fritz Lance M bought $651,800 worth of shares (10,000 units at $65.18), increasing direct ownership by 324% to 13,086 units (SEC Form 4)

    4 - FISERV INC (0000798354) (Issuer)

    11/3/25 4:12:46 PM ET
    $FI
    Real Estate

    Director Agadi Harshavardhan V bought $281,000 worth of shares (100,000 units at $2.81) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    6/20/25 11:34:48 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Merck with a new price target

    Scotiabank initiated coverage of Merck with a rating of Sector Outperform and set a new price target of $105.00

    11/13/25 9:15:08 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fiserv downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Fiserv from Outperform to Neutral and set a new price target of $62.00

    11/5/25 7:27:49 AM ET
    $FI
    Real Estate

    Fiserv downgraded by Argus

    Argus downgraded Fiserv from Buy to Hold

    10/30/25 8:26:22 AM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Conduent Appoints Michael J. Fucci to Board of Directors

    Respected Business Leader and Former Deloitte US Chair Brings Decades of Strategic and Operational Experience Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Michael J. Fucci to its Board of Directors, effective October 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251031043418/en/Michael J. Fucci Mr. Fucci brings more than 40 years of leadership experience, having most recently served as Deloitte US Chair from 2015-2019. In that role, he provided governance and strategic oversight on key priorities including enterprise strategy, l

    10/31/25 8:45:00 AM ET
    $CNDT
    Real Estate

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    REPAY Reports Third Quarter 2025 Financial Results

    Stable growth and continued Free Cash Flow generation in Q3 Retired $73.5 million of convertible notes and repurchased $15.6 million of outstanding shares during Q3 Refining outlook for sustainable growth in Q4 2025 Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today reported financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights   ($ in millions)   Q3 2024     Q4 2024     Q1 2025     Q2 2025     Q3 2025   Revenue   $

    11/10/25 4:05:00 PM ET
    $RPAY
    Real Estate

    Conduent Reports Third Quarter 2025 Financial Results

    Key Q3 2025 Highlights Debt refinance completedRevenue and Adj. Revenue(1): $767MPre-tax Income (Loss): $(38)MAdj. EBITDA Margin(1): 5.2%New Business Signings ACV(2): $111MNet ARR Activity Metric(2) (TTM): $25M FLORHAM PARK, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Conduent Incorporated (NASDAQ:CNDT), a global technology driven business process solutions and services company, today announced its third quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, "Q3 represents not only a quarter where we met guidance on Adjusted Revenue and Adjusted EBITDA Margin, but also the continuation of our drive toward year-over-year revenue growth. New bus

    11/7/25 8:01:00 AM ET
    $CNDT
    Real Estate

    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

    Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3% KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange CAPVAXIVE Sales Were $244 Million GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25% Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7% GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Ch

    10/30/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care